Table 1.
Clinicopathologic characteristics of patients in different risk groups.
| Characteristics | Whole cohort (n = 354) | Log-rank p | Low risk (n = 42) | Moderate risk (n = 156) | High risk (n = 156) | p |
|---|---|---|---|---|---|---|
| Gender | 0.117 | 0.781 | ||||
| Female | 125 (35.3) | 17 (40.5) | 56 (35.9) | 52 (33.3) | ||
| Male | 229 (64.7) | 25 (59.5) | 100 (64.1) | 104 (66.7) | ||
| Race† | 0.079 | 0.229 | ||||
| Asian | 73 (20.6) | 10 (28.6) | 38 (27.1) | 25 (18.7) | ||
| Black | 12 (3.4) | 2 (5.7) | 7 (5.0) | 3 (2.2) | ||
| White | 224 (63.3) | 23 (65.7) | 95 (67.9) | 106 (79.1) | ||
| Age | 0.148 | 0.394 | ||||
| <70 years | 213 (60.2) | 22 (52.4) | 92 (59.0) | 99 (63.5) | ||
| ≥70 years | 141 (39.8) | 20 (47.6) | 64 (41.0) | 57 (36.5) | ||
| Tumor location† | 0.555 | 0.708 | ||||
| Proximal | 45 (12.7) | 5 (12.2) | 19 (12.6) | 21 (14.2) | ||
| Body | 124 (35.0) | 13 (31.7) | 54 (35.8) | 57 (38.5) | ||
| Distal | 132 (37.3) | 18 (43.9) | 56 (37.1) | 58 (39.2) | ||
| EGJ | 39 (11.0) | 5 (12.2) | 22 (14.6) | 12 (8.1) | ||
| Histology classification | 0.057 | 0.002 | ||||
| Signet ring cell | 11 (3.1) | 0 (0.0) | 4 (2.6) | 7 (4.5) | ||
| Diffuse type | 61 (17.2) | 5 (11.9) | 17 (10.9) | 39 (25.0) | ||
| Intestinal type | 162 (45.8) | 25 (59.5) | 85 (54.5) | 52 (33.3) | ||
| Others | 120 (33.9) | 12 (28.6) | 50 (32.1) | 58 (37.2) | ||
| Differentiation grade | 0.295 | 0.001 | ||||
| G1 | 9 (2.5) | 2 (4.8) | 3 (1.9) | 4 (2.6) | ||
| G2 | 128 (36.2) | 24 (57.1) | 68 (43.6) | 36 (23.1) | ||
| G3 | 208 (58.8) | 14 (33.3) | 82 (52.0) | 112 (71.8) | ||
| Gx | 9 (2.5) | 2 (4.8) | 3 (1.9) | 4 (2.6) | ||
| Tumor stage† | <0.001 | 0.044 | ||||
| I | 50 (14.1) | 12 (28.6) | 24 (15.4) | 14 (9.2) | ||
| II | 117 (33.1) | 10 (23.8) | 56 (35.9) | 51 (33.6) | ||
| III | 147 (41.5) | 16 (38.1) | 64 (41.0) | 67 (44.1) | ||
| IV | 36 (10.2) | 4 (9.5) | 12 (7.7) | 20 (13.2) | ||
| Stromal score | 0.014 | <0.001 | ||||
| Low | 127 (35.9) | 38 (90.5) | 67 (42.9) | 22 (14.1) | ||
| High | 227 (64.1) | 4 (9.5) | 89 (57.1) | 134 (85.9) | ||
| Immune score | 0.045 | <0.001 | ||||
| Low | 58 (16.4) | 32 (76.2) | 20 (12.8) | 6 (3.8) | ||
| High | 296 (83.6) | 10 (23.8) | 136 (87.2) | 150 (96.2) |
†
Patients with information unavailable on race (45 patients, 12.7%), tumor location (14 patients, 40%), and tumor stage (4 patients, 1.1%) were excluded from the comparison.